Pharmaceuticals
Fighting Diseases

- Health at Bayer
-
Pharmaceuticals
- Treatments & Therapies
- Innovation & Technologies
- Cell and Gene Therapy
- Sustainability
- Transparency
- News & Stories
- Clinical Trials Explorer
- Transparency Policy
- Personal Health
- Report a Side Effect
- Medical Counterfeits

We Care
01:30
00:00
Latest News
September 21, 2023
More than 70% of farmers have already seen large impacts of climate change on their farm, new global research across 8 countries reveals
September 18, 2023
Not intended for UK Media
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
August 29, 2023
Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn
August 28, 2023
Not intended for UK Media
BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
August 10, 2023
Not intended for U.S. and UK Media – Two-year topline results from the pivotal study PULSAR:
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
June 29, 2023
Not intended for U.S. and UK Media
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years
June 22, 2023
Not intended for U.S. and UK Media
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
June 20, 2023
Crop Science Innovation Summit 2023:
Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres
May 23, 2023
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 3 billion euros
May 16, 2023
Not intended for UK Media
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
May 11, 2023
Bayer Group business performance in the first quarter of 2023:
Slow start to the year as expected
May 10, 2023
Not intended for U.S. and UK Media
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
April 28, 2023
CEO Werner Baumann at the Annual Stockholders’ Meeting:
“Bayer has excellent prospects for the future”
April 05, 2023
Bayer to invest a total of 60 million euros in its Ukrainian seed production site
April 03, 2023
Internationally renowned experts form independent Bayer Bioethics Council
Bayer establishes Bioethics Council
March 21, 2023
UN 2023 Water Conference:
Bayer pledges to help tackle global water crisis with new water strategy
March 20, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
March 01, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
March 01, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for marketing authorization in Japan
February 27, 2023
Not intended for U.S. and UK Media
Nubeqa™ approved for additional indication in Japan
February 10, 2023
Not intended for U.S. and UK Media
Kerendia™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
February 06, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU
January 31, 2023
Bayer to distribute pheromone-based biological crop protection solutions from M2i Group
January 27, 2023
Not intended for U.S. and UK Media
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
January 10, 2023
Not intended for U.S. and U.K. Media
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
December 16, 2022
Not intended for U.S. and UK Media
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
November 29, 2022
Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
November 11, 2022
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity
October 17, 2022
Not intended for U.S. and UK Media
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy
October 05, 2022
Bayer completes sale of its Environmental Science Professional business to Cinven
September 08, 2022
Not intended for U.S. and UK Media
Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients
August 28, 2022
Not intended for U.S. and UK Media
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
August 18, 2022
Bayer supports demining in Ukraine with donation to non-profit “Fondation suisse de déminage”
August 11, 2022
Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture
August 08, 2022
Not intended for U.S. and UK Media
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
June 29, 2022
Not intended for U.S. and UK Media
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
June 28, 2022
Not intended for U.S. and UK Media
Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions
June 23, 2022
Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development
June 21, 2022
Not intended for U.S. and UK Media
Rivaroxaban (Xarelto™) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation
June 08, 2022
Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation
Explore Your Topic
Global Health Policy Blog